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Abstract
The loss of p16 is a signature event in Human Papilloma Virus (HPV)-negative head and neck squamous cell carcinoma
(HNSCC) that leads to increased Cyclin Dependent Kinase 4/6 (CDK) signaling. Palbociclib, a CDK4/6 inhibitor, is active
for the treatment of a subset of HNSCC. In this study, we analyzed patient response data from a phase I clinical trial of
palbociclib in HNSCC and observed an association between prior cisplatin exposure and CDK inhibitor resistance. We
studied the effects of palbociclib on cisplatin-sensitive and -resistant HNSCC cell lines. We found that while palbociclib
is highly effective against chemo-naive HNSCC cell lines and tumor xenografts, prior cisplatin exposure induces
intrinsic resistance to palbociclib in vivo, a relationship that was not observed in vitro. Mechanistically, in the course of
provoking a DNA damage-resistance phenotype, cisplatin exposure upregulates both c-Myc and cyclin E, and
combination treatment with palbociclib and the c-Myc bromodomain inhibitor JQ1 exerts a synergistic anti-growth
effect in cisplatin-resistant cells. These data show the benefit of exploiting the inherent resistance mechanisms of
HNSCC to overcome cisplatin- and palbociclib resistance through the use of c-Myc inhibition.
Introduction
Head and neck squamous cell carcinomas (HNSCC) are
a collection of diseases, diagnosed in ~59,000 people per
year, and responsible for ~12,000 deaths in the U.S.
annually. The majority of HNSCC incidence (~40,000
cases) is attributed to tobacco exposure and smoking1.
The molecular epidemiology of HNSCC is strongly
determined by geographic location and anatomic subsite
that dictates the genetics of these tumors. Among viral-
related cancers, oropharynx cancers are increasingly
caused by human papillomavirus (HPV)2,3. HPV-
associated tumors usually lack mutations or deletions in
cell cycle inhibitory proteins because the cell cycle
machinery is disrupted by the E6 and E7 viral proteins. In
contrast, tobacco-associated cancers acquire the capacity
for unrestrained proliferation by a near ubiquitous loss of
the tumor suppressor protein p16 (CDKN2A)4. p16 loss is
tightly linked to smoking-related cancer and it serves as
the biomarker for HPV-negative HNSCC5,6. In normal
cells, p16 restrains the activity of the cyclin-dependent
kinases 4 and 6 (CDK4/6). In HNSCC tumor cells, the loss
of p16 confers CDK4/6 activity, resulting in hyperpho-
sphorylation of the retinoblastoma protein (Rb)7,8. Thus
far, there has been a distinct lack of therapies targeting the
genetic alterations of HNSCC, with the epidermal growth
factor receptor (EGFR) monoclonal antibody cetuximab
being the only targeted agent to be approved9. Cisplatin
chemotherapy remains the most effective first-line agent
in recurrent and metastatic disease10. The epidemiologic
and molecular data surrounding CDK4/6 and Rb in
HNSCC suggest that CDK4/6 has promise as a ther-
apeutic target in HNSCC.
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Entry from G1 into S-phase is driven by the enzymatic
activity of CDK4 and CDK6, which complex with one of
the regulatory D-type cyclins (D1, D2, or D3)11. CDK4/6-
cyclin D complexes promote hyperphosphorylation of Rb-
family proteins (Rb1, RbL1/p107, and RbL2/p130), of
which Rb1 is the best characterized12. Phosphorylation of
Rb disables its capacity to function as a transcriptional
repressor that sequesters the cell-cycle regulatory E2F
transcription factor. These proteins are required to acti-
vate the S- and M-phase transcriptional programs needed
for successful cell cycle progression. The importance of
CDK4/6 and cyclin D1 in passing this checkpoint is
highlighted by the observation that CDK4 and cyclin D1
are highly amplified in many tumors13. Moreover, CDK4
and cyclin D1 have been shown to be required for
tumorigenesis in several experimental models14–17.
CDK4/6 activity results in the activation of several genes,
including cyclin E1 and cyclin E218. Cyclin E is the reg-
ulatory subunit of CDK2, which further phosphorylates
and completely inactivates Rb, leading to E2F release and
cell cycle progression19,20. The functional relationship
between the various CDK proteins is complex, and their
biochemical roles have not been good predictors of their
genetic function, as elucidated by mouse knockout stu-
dies21. Surprisingly, mice are able to survive inactivation
of both CDK2 and CDK4 genes, and mammalian cell
cycles with normal S-phase kinetics can be completed
successfully in their absence21,22. These findings indicate
the likelihood of significant functional redundancies in the
cell cycle machinery, a probability which explains some of
the difficulties observed with targeting cell cycle kinases.
Therapeutic targeting of the G1-S transition has been a
longstanding goal of oncologic pharmaceutical develop-
ment. Early CDK inhibitors, such as flavopiridol, were
generally non-specific across multiple CDKs and exhib-
ited limited activity in clinical trials23,24. Palbociclib
(PD00332991) is unique as a selective inhibitor of CDK4/
6, and is the first approved CDK inhibitor for the treat-
ment of cancer25. Its original indication was for use in
endocrine-resistant breast cancer. However, clear bio-
markers of response to palbociclib treatment have yet to
be identified, and neither amplification of CCND1 (coding
for cyclin D1) or loss of p16 were definitively linked to
response in breast cancer trials26,27. The lack of associated
biomarkers that predict palbociclib response has fostered
a great interest in the identification of mediators of
therapy response and resistance. To date, pre-clinical
models have offered some elucidation of potential deter-
minants of palbociclib response; primarily, heightened
CDK2 and cyclin E levels that have been observed in
breast and pancreatic cancer models, have been shown to
confer resistance to the drug28,29. Cyclin E is amplified in
breast cancer and is overexpressed in pancreatic cancer30.
Although cyclin E is not amplified or genetically altered in
HNSCC, other inputs, such as EGFR, may elevate CDK2-
cyclin E activity in this disease4.
An interesting feature of targeted therapy development
(including immunotherapies) is that initial clinical testing
usually takes place in the metastatic setting, in patients
who have been exposed to cytotoxic chemotherapy. The
utility of this strategy has some limitation, as it is well
established that chemotherapy can alter the genetic land-
scape of residual tumors31–33. Whole-genome sequencing
of leukemia cells has revealed that chemotherapy can
result in the selection of aggressive clones that resist
therapy34. Exposure to cisplatin can also alter the genome,
resulting in a platinum-specific signature that includes an
increase in a specific mutational profile (increased C > A
mutations)35. Importantly, cisplatin is an essential com-
ponent of both curative and palliative therapy for HNSCC.
In this light, we investigated and now report the effects of
cisplatin exposure on palbociclib sensitivity in both the
pre-clinical and clinical settings in HNSCC. We demon-
strate that cisplatin exposure confers intrinsic cross-
resistance to the CDK4/6 inhibitor palbociclib. Using
in vitro and in vivo analyses, we identify the underlying
mechanism of this resistance, and demonstrate a clinically
relevant mechanism for overcoming this resistance.
Results
Patients with cisplatin-resistant HNSCC show a reduced
response to palbociclib treatment
We previously reported the Phase I results of palbociclib
combined with cetuximab in a cohort of either cetux-
imab- (6/9) or platinum- (4/9) refractory patients36. Pal-
bociclib demonstrated activity in both platinum-sensitive
and -resistant patients, but while the mean time to pro-
gression (TTP) in platinum-sensitive patients was
188.6 days, the mean time to progression in patients with
platinum-resistant disease was shorter at 91 days (Fig. 1a)
(p= 0.0201)37. As this data encompasses a patient set
treated with a combination of cetuximab and palbociclib,
this difference in TTP does not immediately distinguish
the effects of palbociclib versus cetuximab in the pattern
of response and resistance. However, cetuximab has
activity (Fig. 1b) in cisplatin-resistant patients (patient
characteristics presented in Fig. 1c)38, and therefore we
considered that cisplatin exposure may be altering the
efficacy of palbociclib specifically.
Cisplatin resistance predicts palbociclib resistance in mice
bearing HNSCC cell-line-derived xenografts
To investigate the effects of cisplatin exposure on CDK4/
6 inhibition in HNSCC, we identified palbociclib-sensitive
HNSCC cell lines. We grew three commonly used HPV-
negative, p16-negative cell lines (Cal27, SCC1, and SCC25)
as xenografts in immunodeficient mice to ~200mm3 in size
and then treated the mice with palbociclib by oral gavage39.
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Tumor xenografts from each of the three cell lines
responded significantly and nearly uniformly with evident
tumor regression and complete loss of measurable tumor
within ~10 days of treatment (p < 0.0001) (Fig. 2a, c, e).
These data point to a dependency on CDK4/6 in these p16-
negative HNSCC tumor lines.
Next, we determined the IC50 of cisplatin in vitro in
these cell lines, and subsequently increased this value by
serial exposure of cells to increasing levels of cisplatin
using a previously published protocol40 (Supplemental
Fig. 1A). Having established cisplatin-resistant cell lines,
we sought to identify changes to the activity of palbociclib,
but saw no consistent relationship between cisplatin
exposure and palbociclib sensitivity in vitro, as seen by
IC50 measurement (Supplemental Fig. 1B). We show that
palbociclib treatment caused a significant increase in
number of cells in G1, suggesting cell cycle arrest in both
cisplatin-resistant cells and parental cells (Supplemental
Fig. 2A–C). We also showed that with palbociclib
treatment, there was a significant increase in cells accu-
mulating in G2/S in cisplatin-resistant cells compared to
parental lines, and a corresponding decrease in cells
accumulating in G1 in cistplain-resistant cells compared
to parental lines (Supplemental Fig. 2D–F). However,
measuring DNA damage repair capacity in these cells by
comet assay showed that cisplatin-exposed cells exhibited
significantly diminished comet tails 1- and 4-h after
radiation when compared to parental cells, indicating
higher levels of DNA repair41–43 (Supplemental Fig. 3A,
B). Interestingly, Cal27 cisplatin-resistant lines show
increased comet tails compared to parental at baseline,
suggesting decreased DNA repair in this line (Supple-
mental Fig. 3A, panel 1). This correlates with data
showing that Cal27 has an overly active CDK4 pathway
due to truncating mutations in SMAD444, suggesting that
the biological effects of cisplatin treatment, including
increased DNA damage, could still be apparent in the
resistant cell lines.
Fig. 1 Patients with cisplatin-resistant HNSCC show a reduced response to palbociclib treatment. a Percent progression-free survival as shown
by mean time to progression based on cisplatin resistance status in a Phase I clinical trial of palbociclib. Cisplatin-resistant patients (n= 4), cisplatin-
sensitive patients (n= 5). Statistics stated are by Fisher’s exact test, error bars represent SD. b Mean time to progression highlighting disease response
to palbociclib+ cetuximab. c Patient characteristics for Phase I clinical trial (NCT02499120)
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Targeted therapies may have differential effects in vitro
as compared to in vivo45. Therefore, we tested the effects
of cisplatin resistance in vivo by growing the parental and
cisplatin-resistant (cisplatin-R) cells as xenografts in mice.
Cisplatin-resistant cells were grafted into mice and
allowed to form tumors ~200mm3 in size, then treated
with palbociclib. These tumors grew through treatment
unabated at an equivalent rate to untreated tumors in all
cell lines (Fig. 2b, d, f). These data indicate that cisplatin
exposure causes resistance to palbociclib in palbociclib-
naïve cells. Moreover, evidence of resistance is restricted
to tumorigenic growth in vivo, and does not seem to
extend to the two-dimensional tissue culture
environment. To highlight the validity of this effect
in vivo, we performed CD31 staining on sections of
treated tumors, and found that palbociclib treatment
caused a notable decrease in angiogenesis by CD31 when
compared to vehicle control, implicating the micro-
environment of the tumor as having a role in the efficacy
of palbociclib (Supplemental Fig. 4A, B).
Assessment of palbociclib pharmacodynamics in vivo
shows significant CDK4 suppression
To investigate mechanisms of resistance to palbociclib,
we identified the directed targeting and suppression of
CDK4 by palbociclib. CDK4 phosphorylates Rb at serine
Fig. 2 Cisplatin resistance predicts palbociclib resistance in mice bearing HNSCC cell-line-derived xenografts. Tumor growth curves of paired
cisplatin-sensitive (a, c, e) and cisplatin-resistant (b, d, f) HNSCC cell lines, treated for 10 days with palbociclib (70 mg/kg, daily). N= 5 mice per group
and measurements are summarized as mean ± SEM. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, by Student’s t-test)
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780, allowing for hyperphosphorylation of Rb. Tumor
lysates were taken from control and cisplatin-resistant
tumors, and levels of Rb phosphorylation at serine 780
were analyzed by immunoblot (Fig. 3a, b). We showed a
decrease of phosphorylated Rb relative to total Rb in
cisplatin-sensitive cells treated with palbociclib (Fig. 3c).
In cisplatin-resistant cell lines, two of the three also
showed a decrease in phosphorylated Rb relative to total
protein (Fig. 3c), with CAL27 showing a lack of response
due to SMAD4-related palbociclib resistance44. We
therefore show that palbociclib treatment is decreasing
phosphorylation of Rb, regardless of cisplatin-sensitivity
status. Based on these results, we concluded that palbo-
ciclib adequately suppresses its target, CDK4.
Cyclin E and CDK2 expression are enhanced in cisplatin-
resistant samples and further elevated in cisplatin-resistant
samples treated with palbociclib
To understand the phenomenon of unrestrained pro-
liferation in palbociclib-treated tumors, we analyzed the
levels of cell cycle regulatory proteins by immunoblot.
Levels of cyclin A, D, and E were analyzed, as well as
phosphorylated CDK2 and total CDK2 (Supplemental Fig.
5A, C, Fig. 4a), in tumor lysates that were either cisplatin-
sensitive (parental) or cisplatin-resistant. Cyclin D has
been most clearly linked to cisplatin resistance;46 how-
ever, we found no consistent pattern of alteration of
cyclins A or D in cisplatin-resistant samples (Supple-
mental Fig. 5B, D). In contrast, these blots demonstrated
that levels of cyclin E and phosphorylated CDK2 relative
to total CDK2 increased in cisplatin-resistant tumors
compared to parental lines (Fig. 4b).
To identify if palbociclib exposure in tumors might
hyperactivate the cyclin E-CDK2 pathway, subsequently
promoting palbociclib resistance in growing tumors, we
looked at the above regulatory protein levels in tumors
treated with palbociclib. Cisplatin-resistant tumors were
treated daily for 2 weeks with either vehicle or palbociclib,
and harvested 24 h after final dosing. We observed that
cisplatin exposure caused increased cyclin E and CDK2
levels and activity (Fig. 4a, b), which has been previously
linked to cisplatin sensitivity47,48, but also that palbociclib
Fig. 3 Assessment of palbociclib pharmacodynamics in vivo. a Representative immunoblots of Ser780 phospho-Rb, total Rb, and actin for tumor
cell lysates obtained from xenografts of parental cell-line control (gray) and 48 h of palbociclib treatment (red). b Corresponding cisplatin-resistant
cell-line control (black) and 48 h of palbociclib treatment (blue). c Quantification by photo densitometry was performed on bands using Image Lab
Software, and the ratio of phospho-Rb/total Rb was calculated. All quantification is presented as mean ± SD. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001, by Student’s t-test)
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Fig. 4 Cyclin E and CDK2 expression are enhanced in cisplatin-resistant samples and further elevated in cisplatin-resistant samples treated
with palbociclib. a Representative immunoblots of cyclin E, phosphor-CDK2, total CDK2, and actin for tumor cell lysates obtained from untreated
cisplatin naϊve (gray) and cisplatin-resistant xenografts (black). b Quantification by photo densitometry was performed on bands using Image Lab
Software, cyclin E levels were normalized to β-actin loading control, and the ratio of p-CDK2/total CDK2 was calculated. c Representative
immunoblots of cisplatin-resistant tumor cell lysates after 14 days of daily treatment with either vehicle control (black) or palbociclib (blue). Lysates
were harvested 24 h after final dosing. d Accompanying quantification by photo densitometry. All quantification is presented as mean ± SD. (*p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, by Student’s t-test)
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treatment further increased cyclin E and CDK2 activity
(Fig. 4c, d). In addition, tumor growth rates for all lines
treated with palbociclib or control were equivalent (Sup-
plemental Fig. 5E).
Increased c-Myc is a mediator of cisplatin- as well as
palbociclib-resistance
c-Myc is an established mediator of cisplatin resis-
tance49–51, and is also known to upregulate cyclin E52,53.
Therefore, we compared the level of c-Myc in cisplatin-
resistant versus parental tumors and found it to be sig-
nificantly higher in the cisplatin-resistant lysates (Fig. 5a,
b). To address whether this upregulation of c-Myc was an
early or late event, we tested for c-Myc expression at early
and late timepoints and found the induction to occur
early in the process, by day 7 of cisplatin exposure (Sup-
plemental Fig. 6). c-Myc is also linked to cell cycle pro-
gression by inhibiting the expression of p21, a protein that
dephosphorylates and tags Rb for degradation. Based on
this, we hypothesized that the bromodomain inhibitor
JQ1, which is effective at inhibiting c-Myc54,55, might be
effective in cisplatin- and palbociclib-resistant tumors. In
vivo, neither palbociclib nor JQ1 as single agents were
able to markedly overcome the resistance phenotype
conferred by prior exposure to cisplatin, though JQ1 did
exhibit a significant difference from vehicle control (Fig.
5c). Combination of JQ1 and palbociclib was sufficient to
cause a significant reduction in tumor volume that began
after 2 weeks of treatment (Fig. 5c). We hypothesized that
increased c-Myc, either due to baseline levels in cisplatin-
resistant cells or by palbociclib treatment, might be
responsible for this delay in effect. Therefore, a subset of
mice were pre-treated with JQ1 for 7 days before daily
treatment with palbociclib commenced, in an attempt to
reduce the delay. We found that JQ1 pre-treatment did
not change the timing or efficacy of the combination,
suggesting that the delay in efficacy was as a result of a
natural adaptation to palbociclib treatment (Fig. 5c).
Furthermore, we were able to show that this combination
of JQ1 and palbociclib is synergistic in both parental and
cisplatin-resistant cell lines (Supplemental Fig. 7). The
only points corresponding with antagonism are associated
with the lowest concentration of JQ1 that was used to
treat SCC1 and SCC25 cisplatin-resistant cell lines (Sup-
plemental Table 1).
To understand the underlying mechanism, we probed
tumor lysates of single agent or combination treatment
(Fig. 5d) and found that c-Myc expression was suppressed
by JQ1 (Fig. 5e), and that treatment with JQ1 re-expressed
p21 in this system (Fig. 5f). Single agent treatments had
varying effects on Rb phosphorylation, with palbociclib
increasing Rb phosporylation, while treatment with JQ1
resulted in modest a decrease to Rb phosphorylation.
Importantly, in the combination of JQ1 and palbociclib,
activation of Rb was more clearly achieved through the
dual action of palbociclib- and p21-mediated (Fig. 5f) Rb
dephosphorylation (Fig. 5g). These combination results
provide rational for a strategy to mitigate the platinum-
induced palbociclib resistance with the emerging class of
BET bromodomain inhibitors.
Discussion
HPV-negative head and neck squamous cell carcinoma
(HNSCC) are a subset of tumors resulting from tobacco-
related exposure or viral infection. Cisplatin is the most
effective chemotherapy for the treatment of these cancers,
but there is a high rate of clinical failure of cisplatin due to
inherent or acquired resistance56. Unexpectedly, Phase 1
clinical trial data utilizing palbociclib identified that pal-
bociclib has decreased activity in cisplatin-resistant
HNSCC, suggesting a signaling pathway linking the two
therapies and driving potential resistance to treatment.
Understanding the biological shifts that these first-line
therapies enact in cancer will allow for the development,
sequencing, and greater utilization of targeted therapies.
HNSCC is characterized by loss of p16, a tumor sup-
pressor protein that restrains the activity of cyclin-
dependent kinases 4/6 (CDK4/6), and allows for the
hyperphosphorylation of Rb. In normal tissue, the active
state of Rb sequesters E2F transcription factors, thereby
preventing cell cycle progression. Rb becomes inactivated
through a stepwise process of phosphorylation by cyclin-
dependent kinases; initial phosphorylation occurs through
the complex of CDK4/6-cyclin D1, with further phos-
phorylation occurring by the complex of CDK2-cyclin E.
Following hyperphosphorylation, Rb releases E2F, which
then acts as a transcription factor to drive cell cycle
progression to S-phase (Fig. 6a). Palbociclib interrupts
this process at the first step, inhibiting the activity of
CDK4/6/cyclin D1 and blocking further phosphorylation
of Rb (Fig. 6b). Importantly, the CAL27 cell-line has been
shown to have a truncating mutation in SMAD444, which
can cause aberrant activation of the CDK4 pathway57,
downregulation of the TGF-β pathway, and subsequent
resistance to palbociclib treatment58 and other CDK4
inhibitors59. This may explain the limited efficacy of pal-
bociclib in CAL27, and further emphasizes the impor-
tance of identifying therapies that make palbociclib
treatment more effective.
Cyclin E has been shown to overcome the anti-
proliferative activity of palbociclib in Rb positive cells
in vitro, as its cognate kinase CDK2 can inactivate Rb and
promote cell cycle progression29,60. We observed cyclin E
overexpression and hyperactivation of CDK2 in the
cisplatin-resistant lines. Recent studies have implicated
CDK2 as a potential mediator of DNA damage resis-
tance61,62. Therefore, upregulation of cyclin E and p-
CDK2 in cisplatin-resistant cells may contribute to the
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DNA damage response phenotype observed in these cells.
Therefore, the upregulation of cyclin E after cisplatin
exposure was an unexpected finding in our model system.
However, our data is consistent with reports that cisplatin
exposure can activate CDK2, promoting the phosphor-
ylation of Rb and the subsequent release of E2F for con-
tinued cell cycle progression63 (Fig. 6c).
The ability of oncogenes and tumor suppressor genes to
mediate resistance to cytotoxic chemotherapy is well
established. Early experiments with p53 loss of function
revealed a clear effect on chemoresistance64,65. Subse-
quently, c-Myc was found to be a driver of cisplatin-specific
resistance49–51. Our data was consistent with these obser-
vations, showing that c-Myc is significantly upregulated in
Fig. 5 Cisplatin-resistant lines display up-regulated c-Myc expression and treatment with BET family protein inhibitor synergizes with
Palbociclib treatment. a Representative immunoblots of c-Myc and actin for tumor cell lysates harvested from parental and cisplatin-resistant
xenografts after 48 h of treatment with palbociclib. b Quantification of c-Myc and actin for tumor cell lysates harvested from parental (gray) and
cisplatin-resistant (black) xenografts by photo densitometry was performed on bands using Image Lab Software, and normalized to β-actin loading
control for c-Myc. c Tumor growth curves for cisplatin-resistant xenografts treated daily with vehicle (black), single agent palbociclib at 70 mg/kg
(red), single agent JQ1 at 70 mg/kg (blue), combination therapy (green), or combination therapy pre-treated with JQ1 for the first 7 days with
palbociclib added daily starting at day 7 (purple). n= 5 per group, summarized as mean ± SEM. d Representative immunoblots of c-Myc, p21, p-Rb,
total Rb, and actin for tumor cell lysates harvested from xenografts treated with vehicle (black), palbociclib (blue), JQ1 (yellow), or combination
therapy (green) after 28 days of treatment. e Quantification by photo densitometry normalized to β-actin loading control for c-Myc. f Quantification
by photo densitometry normalized to β-actin loading control for p21. g Calculation by photo densitometry normalized to β-actin loading control of
the ratio of p-Rb/total Rb. All quantification is presented as mean ± SD. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, by Student’s t-test)
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cisplatin-exposed cells. To this end, we utilized the BET
bromodomain inhibitor JQ1 to inhibit c-Myc, in conjunc-
tion with palbociclib treatment. The inhibition of c-Myc
allows for the re-expression of p21, driving the depho-
sphorylation of Rb. This overcomes the activity of CDK2-
cyclin E and augments the efficacy of palbociclib (Fig. 6d).
We were able to identify synergy between palbociclib and
JQ1, showing that the combination of these therapies can
overcome cisplatin resistance and be more effective than
either agent alone. This provides a pre-clinical rationale for
future clinical trial development66. It is likely that strategy
using dual BET bromodomain with a CDK4/6 inhibitory
strategy may be useful in treating a significant percentage of
patients with cisplatin-resistant HNSCC.
Fig. 6 Proposed model of JQ1 and palbociclib activity in cisplatin-sensitive and resistant cell lines. a HNSCC cell at baseline. b HNSCC cell
sensitive to cisplatin. c Cisplatin resistance confers palbociclib resistance. d JQ1 combined with palbociclib overcomes cisplatin resistance
Robinson et al. Cell Death and Disease          (2019) 10:867 Page 9 of 13
Official journal of the Cell Death Differentiation Association
Importantly, the relevance of these findings can be
attributed to other cisplatin-resistant cancers. Bromodo-
main inhibitors such as JQ1 have been shown to down-
regulate MYC expression in MYC-amplified tumors,
which sensitizes ovarian cancer cells to platinum-based
therapy67. In addition, the combination of JQ1 with cis-
platin in ovarian cancer cells has shown increased survival
and decreased tumor outgrowth68,69. These findings
highlight the importance of identifying a synergistic
treatment that can overcome the resistance phenotype in
HNSCC and other platinum-resistant cancers.
This data suggests that further exploration into the
mechanism by which c-Myc is upregulated will be
necessary in order to fully understand the role of p21 and
Rb in the response to palbociclib and JQ1. If modifications
to SMAD4 and other factors in the CDK4 pathway have a
role to play in the upregulation of c-Myc, this could
stratify patients that could benefit from combination
therapy. Noting the effect that prior EGFR treatment has
within this system will also be useful to study, as this data
was based on a clinical trial where most of the patients
were exposed to cetuximab. Additionally, we show that
palbociclib treatment reduces levels of total Rb in parental
and cisplatin-resistant cell lines. This is an important area
for future study, as the mechanism of total Rb reduction
may be a consequence of G1 arrest, as previously repor-
ted70, further implicating palbociclib as a cell cycle arrest
agent. Finally, CD31 staining showed a marked decrease
in angiogenesis in palbociclib-treated tumors compared to
vehicle control (Supplemental Fig. 4). This partially
explains the discordance in our in vitro versus in vivo
models. Future work exploring the role of the micro-
environment in response to cisplatin resistance could
yield new avenues for therapeutic exploration.
A major limitation of this research is the cisplatin-
resistant cell lines that were utilized. The cell lines were
created by increasing concentrations of cisplatin treat-
ment, rather than deriving cell lines from cisplatin-
resistant patients or creating a resistance model in vivo.
Furthermore, the microenvironment may play a strong
role in tumor response to combination treatment, sug-
gesting that there may be differences in the biology of
cisplatin-resistant tumors that develop resistance in vivo,
in the presence of microenvironmental factors.
Materials and methods
Cell line maintenance
UM-SCC1 (referred to as SCC1, provided by the Uni-
versity of Michigan), SCC25 (ATCC), and Cal27 (ATCC)
cell lines were cultured at 37 °C in 5% CO2, in Dulbecco’s
Modified Eagle Medium/F12 Ham’s Nutrient Mix
(DMEM/F12) (Gibco #11330–032) supplemented with
10% FBS (Gibco #16140-071), Penicillin-Streptomycin
100 × (10,000 U/mL) (Life Technologies, Grand Island,
NY 15140122), and Hydrocortisone (400 ng/mL) (Sigma
H-0888). Cells were regularly passaged with 0.05% Tryp-
sin/EDTA (500mg/ml Trypsin, 200mg/ml EDTA) (Life
Technologies, Grand Island, NY). All lines were regularly
tested for mycoplasma.
Cisplatin-resistant line generation
Cell lines were exposed to one quarter of the initial IC50
concentration of cisplatin for 1 week, then allowed to
recover until normal growth resumed. Cycles of increas-
ing drug concentration were applied to cell lines until
confirmed resistance by Alamar blue assay.
Xenograft studies
Mouse xenograft experimental protocols were approved
by the Institutional Animal Care and Use Committee
(IACUC) at Washington University in St. Louis. Animals
were maintained and evaluated under pathogen-free
conditions following IACUC guidelines (St. Louis, MO).
Athymic nude mice (4–6-week-old females) were
obtained from Jackson Laboratories (Bar Harbor, ME). A
suspension of 2.0 × 106 cells was injected subcutaneously
into both flanks of each mouse. Length and width of
tumors were measured several times per week, and
volumes were calculated using the formula (length x
width2)/2. Tumors were allowed to reach an average
volume of 200 mm3 before being randomly separated into
treatment groups. Mice were treated with vehicle control,
palbociclib in 0.05 N lactic acid by oral gavage daily at
70 mg/kg body weight, or (+) JQ1 in 5% DMSO, 10% 2-
Hydroxypropyl-β-cyclodextrin by intraperitoneal injec-
tion at 70 mg/kg body weight daily. Five mice per treat-
ment group were utilized for all animal studies, with no
pre-determined size estimate. Investigators were not
blinded to mouse treatment conditions at time of mea-
surement. Mice were killed according to IACUC approved
protocol upon reaching two centimeters diameter in one
dimension, or 1 day after last treatment. Tumor material
was harvested for (1) protein analyses by immunoblot
after snap freezing in liquid nitrogen, and (2) histological
studies by formalin fixation. Tumor growth curves are
summarized as mean ± SEM, with similar variance
between all groups being compared. (*p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001, ****p ≤ 0.0001, by Student’s t-test).
Immunoblot analysis
For xenografted tumor protein expression, three tumor
portions per treatment group were homogenized using
pestles and lysed in RIPA buffer for 20min before soni-
cation, followed by centrifugation for 10min at 4 °C, and
supernatant collection. Total protein concentrations were
determined by Quick Start™ Bradford Assay (BioRad). In
all, 40 µg of protein lysate were added per sample, diluted
in millipure H2O to 20 µL, and diluted further with 5x
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SDS-PAGE Loading Buffer. Samples were boiled at 95 °C
for 5 min and ran through an SDS-PAGE gel. Samples
were electrotransferred onto 0.2 µm PVDF membranes.
Membranes were blocked with 5% milk in PBS-0.1%
Tween20 for 30 min at room temperature. Primary anti-
bodies diluted in 3% BSA, 0.02% NaN3 solution were
incubated overnight on a rocker at 4 °C. After primary
antibody incubation, membranes were washed three times
in 1x PBS-0.1% Tween20 for 8 min each. Species-specific
HRP conjugated secondary monoclonal antibodies were
diluted in 5% milk in 1 × 0.1% Tween20 at a concentration
of 1:5000 and incubated for 1 h at room temperature.
After secondary antibody incubation, membranes were
washed three times in 1 × 0.1% Tween20 for 8 min each.
SuperSignal West Femto or Dura Maximum Sensitivity
Substrate (Thermo) was used for visualization. Unused
lysates were stored at −80 °C. Images were acquired using
Chemidoc XRS+ imaging system and Image Lab Soft-
ware. The antibodies as listed: Cell Signaling: anti-p-Rb
#9307, anti-Cyclin E (he12) #4129, anti-p-CDK2 #2561,
anti-Cyclin D1 #2978, anti-p21 #2947. R&D: anti-CDK2
AF4654, anti-Cyclin A2 AF5999. Abcam: anti-c-Myc
ab32072, anti-Rb ab85607. Sigma: anti-β-Actin A1978.
Quantification of western blots are summarized as mean
± SD, with similar variance between all groups being
compared. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤
0.0001, by Student’s t-test).
Cell cycle analysis
For cell cycle analysis, 1 × 106 cells were treated with
palbociclib for 24 h. Media was removed and cells were
trypsinized and collected for analysis. PI staining solution
was made using 0.1% sodium citrate, 0.03% NP40,
0.02 mg/mL RNase A, and 25 μg/mL propidium iodide.
Cells were resuspended in 350 μL of PI staining solution
(for a final concentration of 1 mg/mL PI) and incubated
for 20min at 4 °C. Staining was analyzed by fluorescence
activated cell sorting (FACS) using a BD FACScan flow
cytometer. In total, 10,000 events were captured and
analyzed using the cell cycle analysis program in FlowJo
(version 10) analysis software (Becton, Dickinson, and
Company). This analysis was conducted in triplicate with
biological replicates. Quantification of analysis is sum-
marized as mean ± SD, with similar variance between all
groups being compared. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001, by Student’s t-test).
JQ1 and palbociclib cell death and synergy studies in vitro
Cells were plated at 4–6 × 103 cells per well in 96-well
plates, depending on cell line. The following day, media
was changed to media supplemented with DMSO, Pal-
bociclib, JQ1, or combination. Doses were dependent on
cell line. For cell death for IC50, Alamar blue diluted 1:10
in media was added, and plates were incubated 2–3 h
before analysis by spectrophotometry. For synergy, plates
were loaded into IncuCycte Zoom platform and assayed
for 72 h. Proliferation data was determined by percent
confluence readout and converted to percent growth
inhibition compared to vehicle control, and cell death was
measured by YOYO-1 Iodide. All assays were conducted
in triplicate with biological replicates. CalcuSyn software
(Cambridge, UK) was utilized to measure combination
index and Graphpad Prism 8 software was utilized for
statistical analysis. Quantification of analysis is summar-
ized as mean ± SD, with similar variance between all
groups being compared. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001, by Student’s t-test).
DNA damage comet assay
Cells were plated at 2 × 105 cells per well in 6-well
plates. The following day, one hour after treatment con-
ditions, cells were trypsinized and centrifuged in 15 mL
tubes prior to irradiation. Cells were treated with either 10
gray or 30 gray ionizing radiation depending on line, using
the Small Animal Radiation Research Platform (SARRP)
by xStrahl. Cells were then assayed using Trevigen Comet
Assay (4252-50-K) according to the Trevigen protocol for
alkaline conditions. DNA was stained using SYBR-Green
fluorescent dye and visualized on an Olympus IX70
microscope with an Olympus DP72 camera using a ×20
objective lens. CellSens Entry software was used for cap-
turing images. OpenComet plugin from ImageJ was used
to analyze the resulting comets. All assays were conducted
in triplicate with biological replicates, and 40 images were
collected per run. Quantification of analysis is summar-
ized as mean ± SD, with similar variance between all
groups being compared. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001, by Student’s t-test).
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